阿斯利康、艾伯维仍是医生心中肿瘤药、自免药第一

MedTrend医趋势
May 26, 2025

在全球制药市场,肿瘤和自身免疫性疾病(自免)领域继续保持主导地位。根据QYR统计及预测,2024年全球肿瘤药物市场销售额超2400亿美元,年复合增长率(CAGR)超10%;2024年全球自免药物市场规模超1700亿美元。对制药厂商而言,一线医生的专业评价始终是药物研发方向优化、市场策略制定及品牌信任构建的核心依据。ZoomRx作为全球领先的战略医疗咨询与技术解决方案服务商,其基于真实美国HCP调研...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10